Study identifies potential strategy to diminish the devastating impacts of traumatic brain injuries

FHS
April 22, 2024
12:50 pm

For the roughly 1.5 million Americans per year who survive a traumatic brain injury, health outcomes vary widely.

GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression | Psychedelic Invest

GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today provided updates and guidance on

October 2, 2023

Secarna Pharmaceuticals publishes new data in Nucleic Acid Therapeutics showcasing strategies to detect and prevent immunostimulatory potential of LNA-modified ASOs – Biotech Investments

EQS-News: Secarna Pharmaceuticals GmbH & Co. KG / Key word(s): Scientific publication Secarna Pharmaceuticals publishes new data in Nucleic Acid Therapeutics showcasing strategies to detect

July 23, 2024

Syndax enters funding agreement with Royalty Pharma for Niktimvo

Niktimvo, an anti-CSF-1R antibody, has received approval in the US for treating chronic GVHD. Credit: Andrei_R/Shutterstock. Syndax Pharmaceuticals has entered a synthetic royalty funding agreement

November 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.